



Clinical trial results:

A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients with Type 2 Diabetes Mellitus

Summary

EudraCT number	2019-003339-53
Trial protocol	DE PL
Global end of trial date	08 October 2021

Results information

Result version number	v1 (current)
This version publication date	23 October 2022
First version publication date	23 October 2022

Trial information

Trial identification

Sponsor protocol code	I8H-MC-BDCL
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04450394
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Number: 17056

Notes:

Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 877CTLilly,
Scientific contact	Available Mon - Fri 9 AM - 5 PM EST, Eli Lilly and Company, 1 8772854559,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 October 2021
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	08 October 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 July 2020
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 56
Country: Number of subjects enrolled	Puerto Rico: 15
Country: Number of subjects enrolled	United States: 126
Country: Number of subjects enrolled	Poland: 42
Country: Number of subjects enrolled	Germany: 39
Worldwide total number of subjects	278
EEA total number of subjects	81

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	199

From 65 to 84 years	79
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study was initially designed as 3 arms: LY3209590 Algorithm 1 (Paper), LY3209590 Algorithm 2 (Digital), and Insulin Degludec. However, it was amended to terminate the "LY3209590 Algorithm 2 (Digital)" arm during early enrollment phase due to technical issues with data entry. (cont'd below)

Pre-assignment

Screening details:

(cont'd) Thus, this arm was excluded from the outcome measure analyses, but safety data was analysed and reported.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	LY3209590 Algorithm 1 (Paper)

Arm description:

Algorithm 1 is a paper-based algorithm where dose adjustments were manually determined by the investigator based on fasting glucose and hypoglycemia data. LY3209590 was provided in a 20 milligram (mg) vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by subcutaneous (SC) injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of ≤ 100 milligrams per deciliter (mg/dL).

Arm type	Experimental
Investigational medicinal product name	LY3209590
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

LY3209590 was provided in a 20 mg vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by SC injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of ≤ 100 mg/dL.

Arm title	Insulin Degludec
------------------	------------------

Arm description:

Insulin degludec was provided as 100 units/milliliter (U/mL) in a prefilled pen. Participants received individually adjusted doses once daily by SC injection with a starting dose of 10 units, during the 26-week treatment period, to achieve target fasting blood glucose of ≤ 100 mg/dL.

Arm type	Active comparator
Investigational medicinal product name	Insulin Degludec
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled pen
Routes of administration	Subcutaneous use

Dosage and administration details:

Insulin degludec was provided as 100 U/mL in a prefilled pen. Participants received individually adjusted doses once daily by SC injection with a starting dose of 10 units, during the 26-week treatment period, to achieve target fasting blood glucose of ≤ 100 mg/dL.

Arm title	LY3209590 Algorithm 2 (Digital)
------------------	---------------------------------

Arm description:

Algorithm 2 is a computer-based algorithm to determine dose adjustments. LY3209590 was provided in a 20 mg vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by SC injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of ≤ 100 mg/dL.

Arm type	Experimental
Investigational medicinal product name	LY3209590
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solvent for solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

LY3209590 was provided in a 20 mg vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by SC injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of ≤ 100 mg/dL.

Number of subjects in period 1	LY3209590 Algorithm 1 (Paper)	Insulin Degludec	LY3209590 Algorithm 2 (Digital)
Started	129	135	14
Received at Least One Dose of Study Drug	129	135	14
Completed	119	121	14
Not completed	10	14	0
Consent withdrawn by subject	6	9	-
Physician decision	-	1	-
Adverse event, non-fatal	2	1	-
Lost to follow-up	-	3	-
Protocol deviation	2	-	-

Baseline characteristics

Reporting groups

Reporting group title	LY3209590 Algorithm 1 (Paper)
Reporting group description:	
Algorithm 1 is a paper-based algorithm where dose adjustments were manually determined by the investigator based on fasting glucose and hypoglycemia data. LY3209590 was provided in a 20 milligram (mg) vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by subcutaneous (SC) injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of ≤ 100 milligrams per deciliter (mg/dL).	
Reporting group title	Insulin Degludec
Reporting group description:	
Insulin degludec was provided as 100 units/milliliter (U/mL) in a prefilled pen. Participants received individually adjusted doses once daily by SC injection with a starting dose of 10 units, during the 26-week treatment period, to achieve target fasting blood glucose of ≤ 100 mg/dL.	
Reporting group title	LY3209590 Algorithm 2 (Digital)
Reporting group description:	
Algorithm 2 is a computer-based algorithm to determine dose adjustments. LY3209590 was provided in a 20 mg vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by SC injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of ≤ 100 mg/dL.	

Reporting group values	LY3209590 Algorithm 1 (Paper)	Insulin Degludec	LY3209590 Algorithm 2 (Digital)
Number of subjects	129	135	14
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	95	92	12
From 65-84 years	34	43	2
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	57.4	59.4	56.3
standard deviation	± 9.9	± 9.1	± 8.8
Gender categorical			
Units: Subjects			
Female	58	59	9
Male	71	76	5
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	61	59	8
Not Hispanic or Latino	68	76	6
Unknown or Not Reported	0	0	0

Race (NIH/OMB)			
Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	2	1	1
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	4	14	1
White	123	119	12
More than one race	0	1	0
Unknown or Not Reported	0	0	0
Region of Enrollment			
Units: Subjects			
Argentina	29	27	0
Puerto Rico	9	4	2
United States	53	61	12
Poland	20	22	0
Germany	18	21	0
Haemoglobin A1c (HbA1c)			
HbA1c is the glycosylated fraction of haemoglobin A. It is measured to identify average blood glucose concentration over prolonged periods of time.			
Units: Percentage of HbA1c			
arithmetic mean	8.05	7.95	8.38
standard deviation	± 0.77	± 0.75	± 0.83

Reporting group values	Total		
Number of subjects	278		
Age categorical			
Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	199		
From 65-84 years	79		
85 years and over	0		
Age continuous			
Units: years			
arithmetic mean			
standard deviation	-		
Gender categorical			
Units: Subjects			
Female	126		
Male	152		
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	128		
Not Hispanic or Latino	150		
Unknown or Not Reported	0		
Race (NIH/OMB)			

Units: Subjects			
American Indian or Alaska Native	0		
Asian	4		
Native Hawaiian or Other Pacific Islander	0		
Black or African American	19		
White	254		
More than one race	1		
Unknown or Not Reported	0		
Region of Enrollment			
Units: Subjects			
Argentina	56		
Puerto Rico	15		
United States	126		
Poland	42		
Germany	39		
Haemoglobin A1c (HbA1c)			
HbA1c is the glycosylated fraction of haemoglobin A. It is measured to identify average blood glucose concentration over prolonged periods of time.			
Units: Percentage of HbA1c			
arithmetic mean			
standard deviation	-		

End points

End points reporting groups

Reporting group title	LY3209590 Algorithm 1 (Paper)
Reporting group description: Algorithm 1 is a paper-based algorithm where dose adjustments were manually determined by the investigator based on fasting glucose and hypoglycemia data. LY3209590 was provided in a 20 milligram (mg) vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by subcutaneous (SC) injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of ≤ 100 milligrams per deciliter (mg/dL).	
Reporting group title	Insulin Degludec
Reporting group description: Insulin degludec was provided as 100 units/milliliter (U/mL) in a prefilled pen. Participants received individually adjusted doses once daily by SC injection with a starting dose of 10 units, during the 26-week treatment period, to achieve target fasting blood glucose of ≤ 100 mg/dL.	
Reporting group title	LY3209590 Algorithm 2 (Digital)
Reporting group description: Algorithm 2 is a computer-based algorithm to determine dose adjustments. LY3209590 was provided in a 20 mg vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by SC injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of ≤ 100 mg/dL.	

Primary: Change From Baseline in Hemoglobin A1c (HbA1c)

End point title	Change From Baseline in Hemoglobin A1c (HbA1c) ^[1]
End point description: HbA1c is the glycosylated fraction of haemoglobin A. It is measured to identify average blood glucose concentration over prolonged periods of time. Least squares (LS) mean change from baseline was analysed by mixed model repeated measures (MMRM) model with treatment, country, Dipeptidyl peptidase IV (DPPIV) (yes/no), Sodium-glucose Cotransporter-2 (SGLT2) (yes/no), baseline body mass index (BMI) [<30 , ≥ 30]], visit, and treatment by visit interaction as fixed effects and the baseline HbA1c as a covariate.	
Analysis Population Description (APD): All participants randomized to either LY3209590 Algorithm 1 (Paper) or Insulin degludec, received at least one dose of study drug and had baseline, post-baseline HbA1c data prior to treatment discontinuation.	
End point type	Primary
End point timeframe: Baseline, Week 26	

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The "LY3209590 Algorithm 2 (Digital)" arm was terminated during early enrollment phase due to technical issues with data entry. Thus, this arm was excluded from the outcome measure analyses.

End point values	LY3209590 Algorithm 1 (Paper)	Insulin Degludec		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	127	130		
Units: Percentage of HbA1c				
least squares mean (standard error)	-1.20 (\pm 0.076)	-1.26 (\pm 0.075)		

Statistical analyses

Statistical analysis title	Change From Baseline in Hemoglobin A1c (HbA1c)
Comparison groups	LY3209590 Algorithm 1 (Paper) v Insulin Degludec
Number of subjects included in analysis	257
Analysis specification	Pre-specified
Analysis type	non-inferiority ^[2]
Parameter estimate	LS Mean Difference
Point estimate	0.06
Confidence interval	
level	90 %
sides	2-sided
lower limit	-0.11
upper limit	0.24

Notes:

[2] - The non-inferiority margin is 0.4%. Non-inferiority is achieved if the upper limit of the 90% Confidence Interval is below 0.4.

Secondary: Change from Baseline in Fasting Serum Glucose

End point title	Change from Baseline in Fasting Serum Glucose ^[3]
-----------------	--

End point description:

LS mean change from baseline was analysed by MMRM model with treatment, country, DPPIV (yes/no), SGLT2 (yes/no), baseline BMI [<30 , ≥ 30]), visit, and treatment by visit interaction as fixed effects and the baseline fasting serum glucose as a covariate.

APD: All participants randomized to either LY3209590 Algorithm 1 (Paper) or Insulin degludec, received at least one dose of study drug and had baseline, post-baseline fasting serum glucose data prior to treatment discontinuation.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 26

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The "LY3209590 Algorithm 2 (Digital)" arm was terminated during early enrollment phase due to technical issues with data entry. Thus, this arm was excluded from the outcome measure analyses.

End point values	LY3209590 Algorithm 1 (Paper)	Insulin Degludec		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	126	130		
Units: milligrams per deciliter (mg/dL)				
least squares mean (standard error)	-50.7 (\pm 2.81)	-58.7 (\pm 2.83)		

Statistical analyses

No statistical analyses for this end point

Secondary: Rate of Documented Hypoglycemia

End point title	Rate of Documented Hypoglycemia ^[4]
-----------------	--

End point description:

Documented hypoglycemia is defined as any time a participant reports a self-monitoring blood glucose <54 mg/dL (3.0 millimole per liter (mmol/L)). Rate of documented hypoglycemia per year during defined period is calculated by the number of documented hypoglycemia events within the period divided by the number of days participant at risk within the period*365.25 days.

APD: All participants randomized to either LY3209590 Algorithm 1 (Paper) or Insulin degludec, received at least one dose of study drug.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline through Week 26

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: The "LY3209590 Algorithm 2 (Digital)" arm was terminated during early enrollment phase due to technical issues with data entry. Thus, this arm was excluded from the outcome measure analyses.

End point values	LY3209590 Algorithm 1 (Paper)	Insulin Degludec		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	129	135		
Units: Events per participant per year				
number (not applicable)	0.21	0.15		

Statistical analyses

No statistical analyses for this end point

Secondary: Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3209590

End point title	Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3209590 ^[5]
-----------------	--

End point description:

AUC of LY3209590 was calculated for individual participants using the participants' Week 26 LY3209590 dose amount and estimated clearance value.

APD: All participants randomized to LY3209590 Algorithm 1 (Paper), received at least one dose of study drug and had evaluable PK data at week 26.

End point type	Secondary
----------------	-----------

End point timeframe:

Week 26

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: PK was evaluated only for experimental arm (i.e., LY3209590 Algorithm 1 (Paper)). The "LY3209590 Algorithm 2 (Digital)" arm was terminated during early enrollment phase due to technical issues with data entry. Thus, this arm was excluded from the outcome measure analyses.

End point values	LY3209590 Algorithm 1 (Paper)			
Subject group type	Reporting group			
Number of subjects analysed	110			
Units: Nanomole*hour per Liter (nmol*hr/L)				
geometric mean (geometric coefficient of variation)	5890 (± 66)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline to Follow-up (up to 31 weeks)

Adverse event reporting additional description:

All randomized participants who received at least one dose of study drug. Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.1
--------------------	------

Reporting groups

Reporting group title	LY3209590 Algorithm 1 (Paper)
-----------------------	-------------------------------

Reporting group description:

Algorithm 1 is a paper-based algorithm where dose adjustments were manually determined by the investigator based on fasting glucose and hypoglycemia data. LY3209590 was provided in a 20 mg vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by SC injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of ≤ 100 mg/dL.

Reporting group title	Insulin Degludec
-----------------------	------------------

Reporting group description:

Insulin degludec was provided as 100 U/mL in a prefilled pen. Participants received individually adjusted doses once daily by SC injection with a starting dose of 10 units, during the 26-week treatment period, to achieve target fasting blood glucose of ≤ 100 mg/dL.

Reporting group title	LY3209590 Algorithm 2 (Digital)
-----------------------	---------------------------------

Reporting group description:

Algorithm 2 is a computer-based algorithm to determine dose adjustments. LY3209590 was provided in a 20 mg vial of reconstitutable lyophilized powder. Participants received individualized LY3209590 loading dose based on the baseline median fasting glucose and body weight by SC injection on day 1 followed by weekly adjustments for the first 12 weeks, then every 4 weeks, of a 26-week treatment period, to achieve target fasting glucose of ≤ 100 mg/dL.

Serious adverse events	LY3209590 Algorithm 1 (Paper)	Insulin Degludec	LY3209590 Algorithm 2 (Digital)
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 129 (4.65%)	4 / 135 (2.96%)	1 / 14 (7.14%)
number of deaths (all causes)	0	1	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
lipoma			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 129 (0.78%)	0 / 135 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

prostatic adenoma alternative dictionary used: MedDRA 24.1 subjects affected / exposed ^[1] occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 71 (0.00%) 0 / 0 0 / 0	1 / 76 (1.32%) 0 / 1 0 / 0	0 / 5 (0.00%) 0 / 0 0 / 0
Injury, poisoning and procedural complications foot fracture alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 129 (0.78%) 0 / 1 0 / 0	0 / 135 (0.00%) 0 / 0 0 / 0	0 / 14 (0.00%) 0 / 0 0 / 0
Cardiac disorders acute myocardial infarction alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 129 (0.00%) 0 / 0 0 / 0	0 / 135 (0.00%) 0 / 0 0 / 0	1 / 14 (7.14%) 0 / 1 0 / 0
coronary artery disease alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 129 (0.00%) 0 / 0 0 / 0	1 / 135 (0.74%) 0 / 1 0 / 0	0 / 14 (0.00%) 0 / 0 0 / 0
myocardial infarction alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 129 (0.78%) 0 / 1 0 / 0	0 / 135 (0.00%) 0 / 0 0 / 0	0 / 14 (0.00%) 0 / 0 0 / 0
Nervous system disorders carotid artery stenosis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 129 (0.78%) 0 / 1 0 / 0	0 / 135 (0.00%) 0 / 0 0 / 0	0 / 14 (0.00%) 0 / 0 0 / 0
Ear and labyrinth disorders			

middle ear inflammation alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 129 (0.78%) 0 / 1 0 / 0	0 / 135 (0.00%) 0 / 0 0 / 0	0 / 14 (0.00%) 0 / 0 0 / 0
Respiratory, thoracic and mediastinal disorders sleep apnoea syndrome alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 129 (0.78%) 0 / 1 0 / 0	0 / 135 (0.00%) 0 / 0 0 / 0	0 / 14 (0.00%) 0 / 0 0 / 0
Psychiatric disorders depression alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 129 (0.00%) 0 / 0 0 / 0	1 / 135 (0.74%) 0 / 1 0 / 0	0 / 14 (0.00%) 0 / 0 0 / 0
Renal and urinary disorders haematuria alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 129 (0.00%) 0 / 0 0 / 0	1 / 135 (0.74%) 0 / 1 0 / 0	0 / 14 (0.00%) 0 / 0 0 / 0
Infections and infestations covid-19 pneumonia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 129 (0.00%) 0 / 0 0 / 0	1 / 135 (0.74%) 0 / 1 0 / 1	0 / 14 (0.00%) 0 / 0 0 / 0
meningitis aseptic alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 129 (0.78%) 0 / 1 0 / 0	0 / 135 (0.00%) 0 / 0 0 / 0	0 / 14 (0.00%) 0 / 0 0 / 0

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.

Justification: There are gender specific adverse events occurring only in male or female participants. The number of participants exposed has been adjusted accordingly.

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	LY3209590 Algorithm 1 (Paper)	Insulin Degludec	LY3209590 Algorithm 2 (Digital)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	18 / 129 (13.95%)	19 / 135 (14.07%)	8 / 14 (57.14%)
Injury, poisoning and procedural complications			
skin laceration			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 129 (0.00%)	0 / 135 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Blood and lymphatic system disorders			
anaemia			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	6 / 129 (4.65%)	2 / 135 (1.48%)	1 / 14 (7.14%)
occurrences (all)	6	2	1
General disorders and administration site conditions			
chest pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 129 (0.00%)	0 / 135 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
injection site pain			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 129 (0.00%)	2 / 135 (1.48%)	1 / 14 (7.14%)
occurrences (all)	0	2	1
Gastrointestinal disorders			
abdominal discomfort			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 129 (0.00%)	0 / 135 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
constipation			

alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	2 / 129 (1.55%)	1 / 135 (0.74%)	1 / 14 (7.14%)
occurrences (all)	3	1	1
diarrhoea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	3 / 129 (2.33%)	7 / 135 (5.19%)	1 / 14 (7.14%)
occurrences (all)	3	8	1
impaired gastric emptying			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 129 (0.00%)	0 / 135 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
infrequent bowel movements			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 129 (0.00%)	0 / 135 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
nausea			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	3 / 129 (2.33%)	7 / 135 (5.19%)	0 / 14 (0.00%)
occurrences (all)	4	7	0
toothache			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 129 (0.00%)	0 / 135 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Respiratory, thoracic and mediastinal disorders			
productive cough			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	1 / 129 (0.78%)	0 / 135 (0.00%)	1 / 14 (7.14%)
occurrences (all)	1	0	1
respiratory disorder			
alternative dictionary used: MedDRA 24.1			
subjects affected / exposed	0 / 129 (0.00%)	0 / 135 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			

dermatitis contact alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 135 (0.00%) 0	1 / 14 (7.14%) 1
skin odour abnormal alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 135 (0.00%) 0	1 / 14 (7.14%) 1
Psychiatric disorders insomnia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 135 (0.00%) 0	1 / 14 (7.14%) 1
Musculoskeletal and connective tissue disorders arthralgia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	3 / 129 (2.33%) 3	7 / 135 (5.19%) 7	0 / 14 (0.00%) 0
intervertebral disc degeneration alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 135 (0.00%) 0	1 / 14 (7.14%) 1
musculoskeletal chest pain alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 135 (0.00%) 0	1 / 14 (7.14%) 1
tendonitis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 135 (0.00%) 0	1 / 14 (7.14%) 1
Infections and infestations fungal skin infection alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 135 (0.00%) 0	1 / 14 (7.14%) 1

mastoiditis alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	0 / 129 (0.00%) 0	0 / 135 (0.00%) 0	1 / 14 (7.14%) 1
urinary tract infection alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	3 / 135 (2.22%) 3	1 / 14 (7.14%) 1
Metabolism and nutrition disorders hyperglycaemia alternative dictionary used: MedDRA 24.1 subjects affected / exposed occurrences (all)	1 / 129 (0.78%) 1	0 / 135 (0.00%) 0	1 / 14 (7.14%) 1

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
08 April 2020	Amendment [a]: This amendment addresses Food and Drug Administration (FDA) feedback.
12 June 2020	Amendment [b]: This provides guidance if COVID-19 related local restrictions impact the participant's ability to attend their onsite study visits as originally scheduled.
14 August 2020	Amendment [c]: The amendment provides information to reflect and reinforce investigational medical device requirements absent in the initial study protocol for Algorithm 2. These requirements are consistent with country regulations where Algorithm 2 will be used.
28 October 2020	Amendment [d]: The amendment provides information to reflect termination of the investigational medical device study arm evaluating the individualized accruing data algorithm (Algorithm 2) investigational device in the study.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study was initially designed as 3 arms: LY3209590 Algorithm 1 (Paper), LY3209590 Algorithm 2 (Digital), and Insulin Degludec. However, it was amended to terminate the "LY3209590 Algorithm 2 (Digital)" arm during early enrollment phase due to tech

Notes: